(Q35825158)

10 August 2017

Pharmacokinetic interaction between amprenavir and delavirdine after multiple-dose administration in healthy volunteers (English)

1 reference

10 August 2017

1 reference

Ulrik S Justesen

1

0 references

Kim Brosen

object named as

Kim Brosen

series ordinal

3

0 references

author name string

Niels A Klitgaard

series ordinal

2

1 reference

10 August 2017

Court Pedersen

series ordinal

4

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 January 2003

1 reference

British Journal of Clinical Pharmacology

10 August 2017

1 reference

10 August 2017

55

1 reference

10 August 2017

1

1 reference

10 August 2017

100-106

1 reference

Delavirdine: clinical pharmacokinetics and drug interactions

10 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884187

Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884187

Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884187

Amprenavir: a review of its clinical potential in patients with HIV infection

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884187

Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884187

A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884187

Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884187

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884187

In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884187

Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884187

Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884187

Pharmacokinetic interaction of amprenavir in combination with efavirenz or delavirdine in HIV-infected children.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884187

Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884187

Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884187

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884187

Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers

24 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1046%2FJ.1365-2125.2003.01734.X

Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1046%2FJ.1365-2125.2003.01734.X

Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/12534646

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Microsomal metabolism of delavirdine: evidence for mechanism-based inactivation of human cytochrome P450 3A

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/12534646

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1046/J.1365-2125.2003.01734.X

1 reference

10 August 2017

1 reference

10 August 2017

PubMed publication ID

12534646

1 reference